May 7, 2020 / 1:10 PM / in a month

BRIEF-Atossa Therapeutics Receives FDA Feedback On Two Ongoing Programs

May 7 (Reuters) - Atossa Therapeutics Inc:

* ATOSSA THERAPEUTICS RECEIVES FDA FEEDBACK ON TWO ONGOING PROGRAMS

* ATOSSA THERAPEUTICS -FDA REQUESTED, CO SUBMIT ADDITIONAL PRE-CLINICAL,OTHER INFORMATION ON AT-H201 BEFORE APPROVING COVID-19 HOPE STUDY

* ATOSSA THERAPEUTICS - FDA RECENTLY PROVIDED WRITTEN INPUT ON ATOSSA’S CLINICAL PATH FOR ORAL ENDOXIFEN TO REDUCE MAMMOGRAPHIC BREAST DENSITY, OR MBD

* ATOSSA THERAPEUTICS -INPUT RECEIVED FROM FDA FOR ORAL ENDOXIFEN WILL INFORM CO’S CLINICAL TRIAL STRATEGY & STUDY DESIGN BOTH IN U.S. & IN STOCKHOLM Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below